| RS1553219199 |
FLG2
|
Health Risk |
Pathogenic |
Peeling skin syndrome 6, Peeling skin syndrome 6 |
| RS1553223152 |
COL11A1
|
Health Risk |
Pathogenic |
Stickler syndrome type 2, Stickler syndrome type 2 |
| RS1553223323 |
ASPM
|
Health Risk |
Likely pathogenic |
— |
| RS1553223496 |
ASPM
|
Health Risk |
Pathogenic |
Microcephaly 5, primary |
| RS1553223544 |
POGZ
|
Health Risk |
Pathogenic |
Intellectual disability-microcephaly-strabismus-behavioral abnormalities syndrome, Intellectual disability-microcephaly-strabismus-behavioral abnormalities syndrome |
| RS1553223897 |
GNAI3
|
Health Risk |
Pathogenic/Likely pathogenic |
Auriculocondylar syndrome 1, Auriculocondylar syndrome 1 |
| RS1553225179 |
ASPM
|
Health Risk |
Pathogenic |
Microcephaly 5, primary |
| RS1553226355 |
GNAT2
|
Health Risk |
Likely pathogenic |
Abnormality of the eye, Abnormality of the eye |
| RS1553226581 |
GNAT2
|
Health Risk |
Likely pathogenic |
— |
| RS1553227015 |
ASPM
|
Health Risk |
Likely pathogenic |
— |
| RS1553227021 |
ASPM
|
Health Risk |
Pathogenic |
Microcephaly 5, primary |
| RS1553227204 |
COL11A1
|
Health Risk |
Likely pathogenic |
— |
| RS1553227645 |
ASPM
|
Health Risk |
Pathogenic |
Microcephaly 5, primary |
| RS1553227742 |
ASPM
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS1553227755 |
ATF6
|
Health Risk |
Pathogenic |
Achromatopsia, Achromatopsia |
| RS1553228009 |
ASPM
|
Health Risk |
Pathogenic |
— |
| RS1553228275 |
ASPM
|
Health Risk |
Pathogenic |
Microcephaly 5, primary |
| RS1553228626 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS1553228653 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease type 1A, Maple syrup urine disease type 1A |
| RS1553229654 |
DBT
|
Health Risk |
Pathogenic/Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS1553229661 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS1553230375 |
AMPD2
|
Health Risk |
Pathogenic |
Pontocerebellar hypoplasia type 9, Pontocerebellar hypoplasia type 9 |
| RS1553230703 |
DBT
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS1553230841 |
DBT
|
Health Risk |
Pathogenic/Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease type 1A |
| RS1553231037 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease type 1A, Maple syrup urine disease type 1A |
| RS1553231167 |
CAMTA1
|
Health Risk |
Pathogenic |
— |
| RS1553231217 |
SPTA1
|
Health Risk |
Pathogenic |
Familial hemolytic anemia, Familial hemolytic anemia |
| RS1553231739 |
PEX10
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder 6A (Zellweger), Peroxisome biogenesis disorder 6B |
| RS1553231783 |
PEX10
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder 6A (Zellweger), Peroxisome biogenesis disorder 6B |
| RS1553231787 |
PEX10
|
Health Risk |
Pathogenic |
Peroxisome biogenesis disorder 6A (Zellweger), Peroxisome biogenesis disorder 6B |
| RS1553231820 |
PEX10
|
Health Risk |
Pathogenic/Likely pathogenic |
Peroxisome biogenesis disorder 6A (Zellweger), Peroxisome biogenesis disorder 6B |
| RS1553231875 |
PEX10
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder 6A (Zellweger), Peroxisome biogenesis disorder 6B |
| RS1553231888 |
PEX10
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder 6A (Zellweger), Peroxisome biogenesis disorder 6B |
| RS1553231896 |
PEX10
|
Health Risk |
Pathogenic/Likely pathogenic |
Peroxisome biogenesis disorder 6A (Zellweger), Peroxisome biogenesis disorder 6B |
| RS1553232007 |
SPTA1
|
Health Risk |
Likely pathogenic |
Hereditary spherocytosis type 3, Hereditary spherocytosis type 3 |
| RS1553232077 |
PEX10
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder 6A (Zellweger), Peroxisome biogenesis disorder 6B |
| RS1553232188 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS1553232197 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease type 1A, Maple syrup urine disease type 1A |
| RS1553232770 |
UFC1
|
Health Risk |
Likely pathogenic |
Neurodevelopmental disorder with spasticity and poor growth, Neurodevelopmental disorder with spasticity and poor growth |
| RS1553232917 |
PEX10
|
Health Risk |
Pathogenic/Likely pathogenic |
Peroxisome biogenesis disorder 6A (Zellweger), Peroxisome biogenesis disorder 6B |
| RS1553232926 |
PEX10
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder 6A (Zellweger), Peroxisome biogenesis disorder 6B |
| RS1553233152 |
DBT
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease type 1A, Maple syrup urine disease type 1A |
| RS1553234309 |
SPTA1
|
Health Risk |
Pathogenic |
Hereditary spherocytosis type 3, Hereditary spherocytosis type 3 |
| RS1553234339 |
COL11A1
|
Health Risk |
Likely pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS1553238271 |
CAMTA1
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS1553238311 |
CAMTA1
|
Health Risk |
Likely pathogenic |
Cerebellar dysfunction with variable cognitive and behavioral abnormalities, Cerebellar dysfunction with variable cognitive and behavioral abnormalities |
| RS1553238760 |
PHGDH
|
Health Risk |
Likely pathogenic |
— |
| RS1553238837 |
CD247
|
Health Risk |
Pathogenic |
Immunodeficiency 25, Immunodeficiency 25 |
| RS1553239242 |
CAMTA1
|
Health Risk |
Pathogenic |
— |
| RS1553240165 |
HMGCS2
|
Health Risk |
Pathogenic |
3-hydroxy-3-methylglutaryl-CoA synthase deficiency, 3-hydroxy-3-methylglutaryl-CoA synthase deficiency |
| RS1553240332 |
CAMTA1
|
Health Risk |
Pathogenic |
— |
| RS1553240525 |
HMGCS2
|
Health Risk |
Pathogenic |
3-hydroxy-3-methylglutaryl-CoA synthase deficiency, 3-hydroxy-3-methylglutaryl-CoA synthase deficiency |
| RS1553240600 |
NEXN
|
Health Risk |
Pathogenic |
Hypertrophic cardiomyopathy 20, Dilated cardiomyopathy 1CC |
| RS1553241079 |
HMGCS2
|
Health Risk |
Pathogenic/Likely pathogenic |
3-hydroxy-3-methylglutaryl-CoA synthase deficiency, 3-hydroxy-3-methylglutaryl-CoA synthase deficiency |
| RS1553241570 |
ASH1L
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 52 |
| RS1553241795 |
WARS2
|
Health Risk |
Pathogenic |
Neurodevelopmental disorder, mitochondrial |
| RS1553242554 |
GJA8
|
Health Risk |
Conflicting classifications of pathogenicity |
Inborn genetic diseases, Cataract 1 multiple types |
| RS1553242577 |
GJA8
|
Health Risk |
Conflicting classifications of pathogenicity |
Cataract 1 multiple types, Cataract 1 multiple types |
| RS1553242856 |
ASH1L
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 52 |
| RS1553243550 |
PTPRC
|
Health Risk |
Likely pathogenic |
Immunodeficiency 104, Immunodeficiency 104 |
| RS1553244022 |
ATP1A2
|
Health Risk |
Likely pathogenic |
— |
| RS1553244740 |
ATP1A2
|
Health Risk |
Conflicting classifications of pathogenicity |
Familial hemiplegic migraine, Familial hemiplegic migraine |
| RS1553244746 |
ATP1A2
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Alternating hemiplegia of childhood 1 |
| RS1553244875 |
ATP1A2
|
Health Risk |
Conflicting classifications of pathogenicity |
Familial hemiplegic migraine, Familial hemiplegic migraine |
| RS1553244881 |
ATP1A2
|
Health Risk |
Pathogenic/Likely pathogenic |
Inborn genetic diseases, Migraine |
| RS1553244883 |
ATP1A2
|
Health Risk |
Pathogenic/Likely pathogenic |
Developmental and epileptic encephalopathy 98, Familial hemiplegic migraine |
| RS1553245038 |
ASH1L
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 52 |
| RS1553245178 |
ATP1A2
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Familial hemiplegic migraine |
| RS1553245183 |
ATP1A2
|
Health Risk |
Likely pathogenic |
— |
| RS1553245659 |
ATP1A2
|
Health Risk |
Pathogenic |
Familial hemiplegic migraine, Familial hemiplegic migraine |
| RS1553245771 |
ATP1A2
|
Health Risk |
Pathogenic |
Familial hemiplegic migraine, Migraine |
| RS1553245780 |
ATP1A2
|
Health Risk |
Conflicting classifications of pathogenicity |
Inborn genetic diseases, Inborn genetic diseases |
| RS1553245857 |
ATP1A2
|
Health Risk |
Pathogenic |
Familial hemiplegic migraine, Migraine |
| RS1553245908 |
ATP1A2
|
Health Risk |
Likely pathogenic |
— |
| RS1553245943 |
ATP1A2
|
Health Risk |
Likely pathogenic |
Inborn genetic diseases, Familial hemiplegic migraine |
| RS1553247020 |
PBX1
|
Health Risk |
Pathogenic |
Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears |
| RS1553247028 |
PBX1
|
Health Risk |
Pathogenic |
Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears |
| RS1553247374 |
ASH1L
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 52 |
| RS1553247592 |
IRF6
|
Health Risk |
Pathogenic |
Orofacial cleft 6, susceptibility to |
| RS1553247595 |
IRF6
|
Health Risk |
Pathogenic |
Van der Woude syndrome 1, Popliteal pterygium syndrome |
| RS1553247602 |
IRF6
|
Health Risk |
Pathogenic |
Van der Woude syndrome 1, Popliteal pterygium syndrome |
| RS1553247675 |
DPYD
|
Health Risk |
Likely pathogenic |
Dihydropyrimidine dehydrogenase deficiency, Dihydropyrimidine dehydrogenase deficiency |
| RS1553247774 |
IRF6
|
Health Risk |
Pathogenic/Likely pathogenic |
Popliteal pterygium syndrome, Van der Woude syndrome |
| RS1553247877 |
IRF6
|
Health Risk |
Likely pathogenic |
Van der Woude syndrome 1, Van der Woude syndrome 1 |
| RS1553248075 |
PBX1
|
Health Risk |
Pathogenic |
Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears |
| RS1553248081 |
PBX1
|
Health Risk |
Pathogenic |
Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears |
| RS1553248110 |
PBX1
|
Health Risk |
Pathogenic |
Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears |
| RS1553248112 |
PBX1
|
Health Risk |
Likely pathogenic |
Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears |
| RS1553248216 |
USH2A
|
Health Risk |
Pathogenic/Likely pathogenic |
Usher syndrome type 2A, Retinitis pigmentosa 39 |
| RS1553248224 |
USH2A
|
Health Risk |
Likely pathogenic |
— |
| RS1553248234 |
USH2A
|
Health Risk |
Pathogenic/Likely pathogenic |
Usher syndrome type 2A, Retinitis pigmentosa 39 |
| RS1553248238 |
USH2A
|
Health Risk |
Conflicting classifications of pathogenicity |
Usher syndrome type 2A, Retinitis pigmentosa 39 |
| RS1553248271 |
IRF6
|
Health Risk |
Likely pathogenic |
Popliteal pterygium syndrome, Van der Woude syndrome |
| RS1553248515 |
TPM3
|
Health Risk |
Pathogenic |
Congenital myopathy 4B, autosomal recessive |
| RS1553248635 |
IRF6
|
Health Risk |
Pathogenic |
Popliteal pterygium syndrome, Van der Woude syndrome |
| RS1553248638 |
IRF6
|
Health Risk |
Pathogenic |
— |
| RS1553248640 |
IRF6
|
Health Risk |
Conflicting classifications of pathogenicity |
Orofacial cleft 6, susceptibility to |
| RS1553248641 |
IRF6
|
Health Risk |
Pathogenic/Likely pathogenic |
Van der Woude syndrome 1, Orofacial cleft 6 |
| RS1553248812 |
USH2A
|
Health Risk |
Likely pathogenic |
— |
| RS1553248832 |
USH2A
|
Health Risk |
Likely pathogenic |
Usher syndrome type 2A, Retinitis pigmentosa 39 |